Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether abciximab is associated with additional
benefit in patients with AMI treated with PCI after high dose clopidogrel loading.
Phase:
Phase 4
Details
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Collaborator:
Technische Universität München
Treatments:
Abciximab Antibodies, Monoclonal Calcium heparin Clopidogrel Heparin Immunoglobulin Fab Fragments